NCT05950724
RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant
Enrolling by Invitation
EARLY_PHASE1Ages 18+InterventionalPreventionNorthwestern UniversityInvestigator-initiated
~20 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:Etanercept Injection [Enbrel]
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Occurrence of kidney dysfunction immediately after lung transplant
Measured over Immediately after lung transplant
+2 more outcomes measured
Conditions
Where it's being run
1 sites across 1 statesIllinois1
Study leadership
- Chitaru Kurihara, MD · PRINCIPAL_INVESTIGATOR · Northwestern University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Planning to undergo transplantation of the lung at Northwestern Memorial Hospital.
Willing and able to read, understand, and be capable of giving informed consent.
Exclusion
Previous or current use of TNFa antibody.
Positive virtual or retrospective crossmatch or highly sensitized (pRA \> 30%) recipients.
Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating.
What this trial measures
- Occurrence of kidney dysfunction immediately after lung transplantImmediately after lung transplant
Measured by serum creatinine blood tests
- Occurrence of kidney dysfunction post-operatively within 1 week after lung transplantWithin 1-7 days after lung transplant
Measured by serum creatinine blood tests
- Occurrence of kidney dysfunction post-operatively within 1 month after lung transplantUp to 30 days after lung transplant
Measured by serum creatinine blood tests